Nippon India Pharma Fund vs WhiteOak Capital Pharma and Healthcare Fund
Direct Plan, Growth option · Data as on 30-10-2026
Nippon India Pharma Fund is a Sectoral fund and WhiteOak Capital Pharma and Healthcare Fund is a Sectoral fund. In the year to 30-10-2026, Nippon India Pharma Fund (Direct) returned 9.1% and WhiteOak Capital Pharma and Healthcare Fund (Direct) returned 19.5%. Nippon India Pharma Fund charges 0.99% a year and WhiteOak Capital Pharma and Healthcare Fund 1.07% (Direct plans). Their portfolios overlap 47.3%: they hold 20 of the same securities.
Nippon India Pharma Fund
Sectoral
- 1 year return
- 9.1%
- Expense ratio
- 0.99%
- NAV
- ₹625.46
WhiteOak Capital Pharma and Healthcare Fund
Sectoral
- 1 year return
- 19.5%
- Expense ratio
- 1.07%
- NAV
- ₹17.44
Which is better, Nippon India Pharma or WhiteOak Capital Pharma and Healthcare? Key differences
It depends on what you want from the fund. These are the differences in numbers, from the data on this page.
- WhiteOak Capital Pharma and Healthcare returned more over 1 year: 19.5% against 9.1%.
- Nippon India Pharma costs less: 0.99% a year against 1.07% (Direct plans).
- Nippon India Pharma fell less in its worst fall since 07-02-2024: −14.7% against −15.4%.
- Nippon India Pharma is the larger fund: ₹9,166 Cr against ₹927 Cr.
- Their portfolios overlap 47.3%: 20 of the same holdings.
Past returns do not promise future returns. This page is information, not investment advice.
Key facts
From each fund's scheme summary document and AMFI
| Fact | Nippon India Pharma Fund | WhiteOak Capital Pharma and Healthcare Fund |
|---|---|---|
| Fund house | Nippon India Mutual Fund | WhiteOak Capital Mutual Fund |
| Category | Sectoral | Sectoral |
| AUM | ₹9,166 Cr (30-09-2026) | ₹927 Cr (30-09-2026) |
| NAV | ₹625.46 (Direct) | ₹17.44 (Direct) |
| Expense ratio (Direct) | 0.99% | 1.07% |
| Expense ratio (Regular) | 1.85% | 2.75% |
| Riskometer | Very High | Very High |
| Benchmark | BSE Healthcare TRI | BSE Healthcare TRI |
| Launch date | 05-06-2004 | 06-02-2024 |
| Minimum investment | ₹5,000 | ₹500 |
| Lock in | None | None |
| Fund managers | Sailesh Raj Bhan | Ramesh Mantri, Piyush Baranwal, Dheeresh Pathak, Ashish Agrawal, Trupti Agrawal |
| Exit load | Exit load of 1% if redeemed within 1 month. | Nil |
Nippon India Pharma vs WhiteOak Capital Pharma and Healthcare: Returns Comparison
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Fund | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| Nippon India Pharma Fund (Direct) | −0.76% | −2.52% | +7.84% | +9.05% | +18.56% | +14.19% | +15.18% |
| WhiteOak Capital Pharma and Healthcare Fund (Direct) | +0.92% | +1.33% | +17.99% | +19.53% | -- | -- | -- |
| Sectoral average | −1.70% | −4.49% | +2.30% | −0.58% | -- | -- | -- |
Category average: the average of the 20 Sectoral funds, same plan type.
Nippon India Pharma vs WhiteOak Capital Pharma and Healthcare: Year-wise Returns
| Year | Nippon India PharmaNippon India Pharma | WhiteOak Capital Pharma and HealthcareWhiteOak Capital Pharma and Healthcare | BSE Healthcare TRI |
|---|---|---|---|
| 2026to date | +9.76% | +22.83% | +15.08% |
| 2025 | −2.46% | +1.84% | −2.72% |
| 2024 | +35.26% | -- | +44.30% |
| 2023 | +40.36% | -- | +37.97% |
| 2022 | −9.06% | -- | −11.50% |
| 2021 | +25.12% | -- | +21.54% |
Nippon India Pharma vs WhiteOak Capital Pharma and Healthcare: Rolling Returns
Every holding period of both funds, against BSE Healthcare TRI, the benchmark of both
Rolling returns
Every 1-year holding period, 424 of them, one for each trading day from 07-02-2025 to 30-10-2026: the yearly return (CAGR) of each, plotted on the day it ended. One lucky or unlucky start day cannot flatter or hide a fund.
Nippon India Pharma Fund (Direct)
WhiteOak Capital Pharma and Healthcare Fund (Direct)
BSE Healthcare TRI
to
Mar 2025Jul 2024
to
Jul 2025Oct 2024
to
Oct 2025Feb 2025
to
Feb 2026May 2025
to
May 2026Sept 2025
to
Sept 2026
How the periods spread
| Fund | Below 0% | 0-5% | 5-10% | 10-15% | 15-20% | 20-25% | Above 25% | Mean | Median | Lowest | Highest | Beat benchmark |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nippon India Pharma | 11.3 | 22.4 | 27.1 | 25.5 | 13.4 | 0.2 | 0.0 | 7.9% | 8.3% | −4.3% | 20.2% | 17% |
| WhiteOak Capital Pharma and Healthcare | 0.0 | 6.6 | 14.9 | 16.3 | 18.6 | 19.3 | 24.3 | 18.0% | 18.4% | 0.6% | 35.5% | 100% |
| BSE Healthcare TRI | 9.4 | 19.1 | 17.2 | 25.0 | 20.5 | 8.7 | 0.0 | 10.2% | 11.0% | −3.7% | 24.8% | -- |
The table shows the % of periods in each return band; a darker cell holds more of them. Lumpsum: the yearly rate (CAGR) from a period's first NAV to its last. SIP: the XIRR of the monthly instalments. The benchmark is BSE Healthcare TRI, over the same periods. "Beat benchmark" counts the periods in which the fund did better. Every fund is measured over the days all of them have, from 07-02-2024. Past returns do not promise future returns.
Nippon India Pharma vs WhiteOak Capital Pharma and Healthcare: SIP and Lumpsum Returns
What the same monthly or one-time investment would be worth in each fund today, from their own NAV history
Growth of an investment
₹10,000 on the first trading day of every month, from 01-02-2024 to 30-10-2026: 33 instalments, ₹3,30,000 in all.
| Investment | Invested | Value now | Gain | Return a year |
|---|---|---|---|---|
| Nippon India PharmaNippon India Pharma Fund (Direct) | ₹3,30,000 | ₹3,74,548 | ₹44,548 | 9.2% |
| WhiteOak Capital Pharma and HealthcareWhiteOak Capital Pharma and Healthcare Fund (Direct) | ₹3,30,000 | ₹4,37,625 | ₹1,07,625 | 21.2% |
Nippon India PharmaNippon India Pharma Fund (Direct)
WhiteOak Capital Pharma and HealthcareWhiteOak Capital Pharma and Healthcare Fund (Direct)
Amount invested
From each plan's published NAV (Growth option), over the same days. Return a year: XIRR for a SIP, CAGR for a lumpsum, shown for a year or more. It does not include exit load, stamp duty or tax. Past returns do not promise future returns.
Nippon India Pharma vs WhiteOak Capital Pharma and Healthcare: Risk and Drawdowns
How much each fund swings, and the worst fall over the same days
Risk and return
| Measure | Nippon India Pharma Fund (Direct) | WhiteOak Capital Pharma and Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +9.05% | +19.53% |
| Standard deviation | 12.27% | 13.75% |
| Sharpe ratio | 0.31 | 1.04 |
| Sortino ratio | 0.45 | 1.57 |
| Maximum drawdown | −9.6% (23-10-2026) | −9.8% (23-10-2026) |
| Beta | 0.87 | 0.97 |
| Alpha | −2.40% | +7.36% |
From daily NAVs, 30-10-2025 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | Nippon India Pharma Fund (Direct) | WhiteOak Capital Pharma and Healthcare Fund (Direct) |
|---|---|---|
| Return (CAGR) | +17.18% | +22.30% |
| Standard deviation | 15.19% | 14.35% |
| Sharpe ratio | 0.73 | 1.14 |
| Sortino ratio | 1.06 | 1.62 |
| Maximum drawdown | −24.0% (29-05-2017) | −15.4% (28-02-2025) |
| Beta | 0.85 | 0.97 |
| Alpha | +3.72% | +7.59% |
From daily NAVs, 02-01-2013 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
Nippon India Pharma Fund (Direct)
WhiteOak Capital Pharma and Healthcare Fund (Direct)
BSE Healthcare TRI
| Fund | Worst fall | High before it | Bottom | Back at the high | Time to climb back | Below its high today |
|---|---|---|---|---|---|---|
| Nippon India Pharma Fund (Direct) | −14.7% | 02-01-2025 | 28-02-2025 | 24-07-2025 | 5 months | −4.3% |
| WhiteOak Capital Pharma and Healthcare Fund (Direct) | −15.4% | 02-01-2025 | 28-02-2025 | 14-07-2025 | 4 months | −3.0% |
| BSE Healthcare TRI | −16.2% | 02-01-2025 | 28-02-2025 | 29-07-2025 | 5 months | −3.8% |
From daily values since 07-02-2024, the first day every fund has.
Rolling standard deviation
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 1-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
Nippon India Pharma Fund (Direct)
WhiteOak Capital Pharma and Healthcare Fund (Direct)
BSE Healthcare TRI
Against BSE Healthcare TRI
| Fund | Up capture | Down capture | Tracking error |
|---|---|---|---|
| Nippon India Pharma Fund (Direct) | 85% | 94% | 4.09% |
| WhiteOak Capital Pharma and Healthcare Fund (Direct) | 116% | 90% | 3.43% |
From month-end values since 07-02-2024. Up capture: a fund's average month when the benchmark rose, as % of the benchmark's; above 100% it gained more. Down capture: the same for months the benchmark fell; below 100% it fell less. Tracking error: how far the monthly returns strayed from the benchmark's, a year; an index fund aims near 0.
Nippon India Pharma vs WhiteOak Capital Pharma and Healthcare: Portfolio Overlap
From each fund's latest monthly portfolio: Nippon India Pharma Fund, September 2026; WhiteOak Capital Pharma and Healthcare Fund, September 2026
Holdings in common
- Overlap
- 47.3%
- Held by both
- 20
- Only in Nippon India Pharma
- 16
- Only in WhiteOak Capital Pharma and Healthcare
- 39
| Security | % of Nippon India Pharma | % of WhiteOak Capital Pharma and Healthcare |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 11.71% | 7.11% |
| Divi's Laboratories Limited | 7.10% | 8.36% |
| Apollo Hospitals Enterprise Limited | 4.89% | 3.75% |
| Cipla Limited | 6.01% | 3.68% |
| Sai Life Sciences Limited | 3.92% | 3.28% |
| IPCA Laboratories Limited | 2.87% | 2.88% |
| Thyrocare Technologies Limited | 2.24% | 2.27% |
| Dr. Lal Path Labs Limited | 2.17% | 2.35% |
| Ajanta Pharma Limited | 3.61% | 2.01% |
| Max Healthcare Institute Limited | 2.70% | 1.84% |
| Aurobindo Pharma Limited | 1.65% | 2.09% |
| Narayana Hrudayalaya Limited | 1.61% | 1.61% |
| Vijaya Diagnostic Centre Limited | 2.62% | 1.56% |
| Mankind Pharma Limited | 4.38% | 1.20% |
| Anthem Biosciences Limited | 1.19% | 1.57% |
| Fortis Healthcare Limited | 1.13% | 1.36% |
| Piramal Pharma Limited | 2.24% | 1.06% |
| Gland Pharma Limited | 2.53% | 0.93% |
| Molbio Diagnostics Limited | 0.54% | 1.15% |
| Biocon Limited | 1.01% | 0.42% |
Overlap: for each holding both funds own, the smaller of its two weights, added up. 47.3% means 47.3% of each fund's money sits in positions the other also holds. Matched by ISIN. Cash and hedged positions are left out.
Largest holdings only in Nippon India Pharma Fund
| Security | % of fund |
|---|---|
| Lupin Limited | 6.17% |
| Dr. Reddy's Laboratories Limited | 5.45% |
| GlaxoSmithKline Pharmaceuticals Limited | 3.11% |
| MedPlus Health Services Limited | 2.53% |
| Abbott India Limited | 2.32% |
Largest holdings only in WhiteOak Capital Pharma and Healthcare Fund
| Security | % of fund |
|---|---|
| Torrent Pharmaceuticals Limited | 6.26% |
| Laurus Labs Limited | 3.91% |
| Zydus Lifesciences Limited | 2.81% |
| Neuland Laboratories Limited | 2.60% |
| Corona Remedies Limited | 2.34% |
Asset and sector split
Share of each fund, from its latest monthly portfolio
Asset allocation
| Asset | Nippon India Pharma | WhiteOak Capital Pharma and Healthcare |
|---|---|---|
| Equity | 97.3% | 90.7% |
| Debt | 0.0% | 3.1% |
| Cash and others | 2.7% | 6.1% |
Market cap of stocks
| Market cap | Nippon India Pharma | WhiteOak Capital Pharma and Healthcare |
|---|---|---|
| Large Cap | 29.7% | 29.2% |
| Mid Cap | 39.0% | 21.7% |
| Small Cap | 28.0% | 37.5% |
| Not on AMFI's list | 0.5% | 2.4% |
Share of the whole fund. Groups follow AMFI's latest list: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Largest sectors
| Sector | Nippon India Pharma | WhiteOak Capital Pharma and Healthcare |
|---|---|---|
| Pharmaceuticals & Biotechnology | 74.0% | 61.2% |
| Healthcare Services | 20.3% | 23.0% |
| Chemicals & Petrochemicals | 0.0% | 3.3% |
| Retailing | 2.5% | 0.0% |
| Consumer Durables | 0.0% | 1.8% |
| Healthcare Equipment & Supplies | 0.5% | 1.4% |
The six largest sectors of each fund's stocks, % of the fund.
Nippon India Pharma vs WhiteOak Capital Pharma and Healthcare: Expense Ratio
What each plan charges a year, from AMFI's expense ratio file
| Charge | Nippon India Pharma Fund | WhiteOak Capital Pharma and Healthcare Fund |
|---|---|---|
| Total expense ratio (Direct) | 0.99% | 1.07% |
| Base expense ratio (Direct) | 0.79% | 0.54% |
| Total expense ratio (Regular) | 1.85% | 2.75% |
| Base expense ratio (Regular) | 1.52% | 1.96% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, transaction costs, and levies with GST.
More comparisons
Each fund against the others of its category
Compare Nippon India Pharma with
Compare WhiteOak Capital Pharma and Healthcare with
Nippon India Pharma Fund vs WhiteOak Capital Pharma and Healthcare Fund: Frequently Asked Questions
What is the difference between Nippon India Pharma Fund and WhiteOak Capital Pharma and Healthcare Fund?
Nippon India Pharma Fund is a Sectoral fund, WhiteOak Capital Pharma and Healthcare Fund is a Sectoral fund, run by Nippon India Mutual Fund and WhiteOak Capital Mutual Fund. Their portfolios overlap 47.3%. Nippon India Pharma Fund charges 0.99% a year and WhiteOak Capital Pharma and Healthcare Fund 1.07%.
Which has given higher returns, Nippon India Pharma Fund or WhiteOak Capital Pharma and Healthcare Fund?
Over 1 year: Nippon India Pharma Fund +9.05%, WhiteOak Capital Pharma and Healthcare Fund +19.53%. As on 30-10-2026. Past returns do not promise future returns.
Which has the lower expense ratio, Nippon India Pharma Fund or WhiteOak Capital Pharma and Healthcare Fund?
Nippon India Pharma Fund charges less: 0.99% a year against 1.07%. These are the Direct plans' total expense ratios reported to AMFI.
How much do Nippon India Pharma Fund and WhiteOak Capital Pharma and Healthcare Fund overlap?
47.3%. They hold 20 of the same securities, the largest shared ones being SUNPHARMA, DIVISLAB, APOLLOHOSP. From each fund's latest monthly portfolio.
Which is riskier, Nippon India Pharma Fund or WhiteOak Capital Pharma and Healthcare Fund?
On SEBI's riskometer, Nippon India Pharma Fund is rated Very High and WhiteOak Capital Pharma and Healthcare Fund Very High. Over 1 years, the standard deviation of daily returns was 12.27% and 13.75% a year.
Can I invest in both Nippon India Pharma Fund and WhiteOak Capital Pharma and Healthcare Fund?
Yes. 47.3% of each fund's money sits in the same holdings, so a large part of the two investments would move together.
Who manages Nippon India Pharma Fund and WhiteOak Capital Pharma and Healthcare Fund?
Nippon India Pharma Fund: Sailesh Raj Bhan. WhiteOak Capital Pharma and Healthcare Fund: Ramesh Mantri, Piyush Baranwal, Dheeresh Pathak, Ashish Agrawal, Trupti Agrawal.
Sources: NAV and expense ratio from AMFI. Holdings from each fund house's monthly portfolio statement. Fund facts from each scheme summary document.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.